微生物药物产量理性化提高的策略及其研究进展  

The strategies and research progresses of rational improvement of the yield of microbial drug

作　　者：吴蕴[1] 宋晨阳 陈文青[1] 

机构地区：[1]武汉大学药学院,组合生物合成与新药发现教育部重点实验室,湖北武汉430072 [2]延边春雷生物药业有限公司,吉林延吉133000

出　　处：《微生物学报》2016年第3期454-460,共7页Acta Microbiologica Sinica

基　　金：国家自然科学基金(31270100)~~

摘　　要：微生物药物(Microbial drug)是一类结构复杂多样,生物活性显著的小分子化合物。微生物药物产量决定了其后续的可开发性与使用成本。传统育种方法提高微生物药物产量效果明显,但随机性强且成本高昂,然而合成生物学的兴起为微生物药物产量理性化提高注入了全新活力。本文从启动子的工程化应用、前体供应、基因组重排等方面,综述了近年来合成生物学策略在放线菌来源的微生物药物产量理性化提高方面所取得的相关研究进展。Microbial drug is a large family of small molecules with unusual structural features and potent bioactivities.The production of microbial drug is crucial for its subsequent development and cost. Traditional breeding strategies for microbial drug production have been demonstrated to be remarkably effective, but they have also indicated the drawback of exceptional randomness and high cost. Synthetic biology has recently promised a revival for the rational enhancement of microbial drugs. In this review, we mainly discuss the recent progress from the aspects of promoter engineering, precursor supply, genome shuffling and etc., to delineate the application of the synthetic biology strategies to enhance the production of the microbial drugs, particularly, produced by actinomycetes.

关 键 词：微生物药物 产量理性化提高 传统育种策略 合成生物学 

分 类 号：R915[医药卫生—微生物与生化药学]